<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F113D73A-143F-41B6-9680-98AF837D51DF"><gtr:id>F113D73A-143F-41B6-9680-98AF837D51DF</gtr:id><gtr:name>University of Antwerp</gtr:name><gtr:address><gtr:line1>Universiteitsplein 1</gtr:line1><gtr:line4>Antwerp</gtr:line4><gtr:line5>B-2610</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/84F33A16-13EA-48F9-886F-851E3DD949EA"><gtr:id>84F33A16-13EA-48F9-886F-851E3DD949EA</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123182015"><gtr:id>07E787BD-C78F-4A38-8411-6E69F45D6CDA</gtr:id><gtr:title>Molecular basis of frontotemporal dementia and related disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123182015</gtr:grantReference><gtr:abstractText>Frontotemporal dementia is the second most common cause of dementia in people under the age of 65, after Alzheimers disease. We have recently identified a gene, called CHMP2B, which causes frontotemporal dementia in a large family who inherit the disease in every generation. CHMP2B is active in tiny structures found inside brain cells called endosomes, whose failure has also been implicated in Alzheimers disease. We are now studying in more detail how CHMP2B can cause the death of brain cells.||We are analysing the brains of people who have died from dementia to determine whether they have similar changes in their brain cells to patients with a problem with CHMP2B. We are also growing cells with disease causing versions of CHMP2B in culture dishes to try and work out what parts of the cell are going wrong and lead the cell to die. Finally, are analysing mice with disease causing versions of CHMP2B. These mice will be very important to help understand how brains cells die over time, which specific brain areas die, and to test possible drugs that could help cure dementia caused by the CHMP2B gene. It is possible that this research will also help explain why brain cells die in Alzheimers disease.</gtr:abstractText><gtr:technicalSummary>Frontotemporal dementia (FTD) is the second most common form of presenile dementia after Alzheimers disease, making it of major clinical significance. We recently showed that a mutation in the CHMP2B gene was responsible for causing FTD in a large Danish family. The CHMP2B mutation leads to the formation of aberrant CHMP2B proteins that affect endosomal function. There is accumulating evidence that endosomal dysfunction may underlie a number of neurodegenerative diseases including Alzheimers disease and motor neurone disease.||The aim of this programme is to further understand the role of CHMP2B and related genes in the pathogenesis of FTD and other neurodegenerative diseases. This research may give insight into the aetiology of a number of neurodegenerative disorders.||The specific research objectives are:||1) To develop mouse models of CHMP2B induced neurodegeneration.|This will allow further characterisation of the pathogenic cascade that leads to disease and the eventual testing of therapeutics. We will use transgenic mice over-expressing CHMP2B mutant proteins as well as CHMP2B knockout mice. Development of these mouse lines will also allow crossing to other mouse models of neurological diseases in order to identify common pathways of neurodegeneration.||2) To further characterise CHMP2B and related genes in human tissue.|This aim includes genetic analysis to understand the wider impact of CHMP2B and related genes in neurological diseases. We are also analysing brain tissue from patients with a range of neurological diseases to identify CHMP2B induced pathologies as well as endosomal pathology.||3) To develop cell culture models of CHMP2B related cell death|This aim will allow us to study the mechanisms and cell death pathways that lead to neurodegeneration in well characterised cell lines and in primary neuronal cultures. The use of cell culture allows a number of different cell death paradigms to be investigated, as well interactions with other neurological disease genes.||In summary, the research aims of this programme may give insight into the pathogenesis of FTD as well as other neurodegenerative disorders.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-23</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1110433</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>FReJA consortium</gtr:description><gtr:id>6077CA65-4200-4873-A6F8-36B806EC8EDB</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:outcomeId>4DBAAB06231-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>FReJA consortium</gtr:description><gtr:id>F2BF0F5D-652E-4366-8A70-11EBB12332DB</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:outcomeId>4DBAAB06231-5</gtr:outcomeId><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Antwerp</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Belgian CHMP2B collaboration</gtr:description><gtr:id>25911F9F-C0A1-4E38-A407-4FD3069F518C</gtr:id><gtr:impact>Publications 17956895, 20223751</gtr:impact><gtr:outcomeId>472ED9845BA-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples</gtr:partnerContribution><gtr:piContribution>We have modelled the effect of a CHMP2B mutation found in Belgian frontotemporal dementia patient. We are continuing this collaboration by characterising cells from the Belgian patient.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Norwegian autophagy collaboration</gtr:description><gtr:id>BD0FE3FF-F1AC-4AB5-88E3-F2FB6EF3086C</gtr:id><gtr:impact>Publication 17984323</gtr:impact><gtr:outcomeId>E9EA40C4692-1</gtr:outcomeId><gtr:partnerContribution>Provision of expertise in autophagy</gtr:partnerContribution><gtr:piContribution>We provided constructs and expertise in frontotemporal dementia research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>FReJA consortium</gtr:description><gtr:id>0B751ED2-0406-47CB-8B04-0E7A03DC7292</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:outcomeId>4DBAAB06231-4</gtr:outcomeId><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Medicine</gtr:department><gtr:description>FReJA consortium</gtr:description><gtr:id>9AA79B13-274B-443B-B3B2-9EEB619A30EE</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:outcomeId>4DBAAB06231-2</gtr:outcomeId><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>FReJA consortium</gtr:description><gtr:id>E9344AB7-35EF-415D-AC48-EE94C439B554</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:outcomeId>4DBAAB06231-3</gtr:outcomeId><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Patient Feedback (Denmark)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0BDDADD7-1240-4DC7-B4DB-706E60755258</gtr:id><gtr:impact>An update on research findings was provided to approximately 40 family members with inherited dementia. This sparked discussion regarding genetic testing for the condition and volunteering for blood donation.

31 family members donated blood for research.</gtr:impact><gtr:outcomeId>gnsnhXsoNG2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lay public talk (Cheltenham Science Festival)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B91F5020-C0C5-42B8-B872-D49DC19B22DA</gtr:id><gtr:impact>At least 50 members of the lay public attended and it was followed by a lengthy Q and A. Many members of the audience personally expressed their enthusiasm for my talk.

I was invited to speak at schools for the organisation Understanding Animal Research</gtr:impact><gtr:outcomeId>ets1YgTey62</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient group talk (St Georges)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>88688647-9117-4E7A-BA3A-213F16B49675</gtr:id><gtr:impact>~25 early-onset dementia patients and their carers attended a talk about my research into dementia followed by a Q and A.

Several audience members enquired about donating brains for research and about donating money for dementia research</gtr:impact><gtr:outcomeId>o3knGr8D83L</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ethics panel presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C16DB6F1-7FA6-4E03-BD45-1C91EBD541BF</gtr:id><gtr:impact>Presentation of our research to a mixed academic and lay ethics review panel

Greater understanding of our research by non-academics.</gtr:impact><gtr:outcomeId>0E2300F3D29</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ART Press Release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A751D1B5-F606-4A6F-8B7F-C2876D44E01C</gtr:id><gtr:impact>Press release from the Alzheimer's Research Trust to announce their funding of a Pilot Project Grant in Dr Isaacs' lab. Press release was posted on the UCL and Alzheimer's Research Trust websites.

Greater awareness of our research.</gtr:impact><gtr:outcomeId>2F99656D120</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>77500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL Hospitals Clinical Research Development Committee Project Grant</gtr:description><gtr:end>2009-05-02</gtr:end><gtr:fundingOrg>University College London Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>CE45F4C8-8F31-4D7F-9585-F3E20317E5DE</gtr:id><gtr:outcomeId>89C5EE4D9900</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>480869</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>New Investigator Research Grant</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E81D9E0D-EC3B-487E-927F-7B6023090DFB</gtr:id><gtr:outcomeId>SpV5F1R3UKx</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>83100</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fidelity Biosciences Research Initiative/Fidelity Biosciences</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Fidelity Biosciences</gtr:fundingOrg><gtr:id>CA5DD956-7E3C-4127-BA75-BF74F765919C</gtr:id><gtr:outcomeId>GknsUCLUJxf0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Development Gap Funding</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:id>B7464465-0529-4368-B643-A1CAC1FF3C58</gtr:id><gtr:outcomeId>2A5C01456510</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49760</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Eli Lilly collaboration grant</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:id>BB43F6F7-EEE1-4693-B778-E80C81E698EE</gtr:id><gtr:outcomeId>Gw3zvgb4s28</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ART Pilot Grant</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>29962B56-823D-411A-AD25-516AA2E78FE4</gtr:id><gtr:outcomeId>C7592F506310</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mutations in the CHMP2B gene cause dementia. We generated and characterised CHMP2B knockout mice and transgenic mice expressing mutant and normal forms of human CHMP2B.</gtr:description><gtr:id>F515DC63-478F-4D9B-92A4-717D9E894C40</gtr:id><gtr:impact>Publication:
Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Ghazi-Noori S, Froud KE, Mizielinska S, Powell C, Smidak M, Fernandez de Marco M, O'Malley C, Farmer M, Parkinson N, Fisher EM, Asante EA, Brandner S, Collinge J, Isaacs AM. Brain. 2012 Mar;135(Pt 3):819-32.
PMID: 22366797</gtr:impact><gtr:outcomeId>jVrJpZiEYhW</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>CHMP2B mouse models</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://europepmc.org/abstract/MED/22366797</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5CACD564-8C03-48DC-88D3-E704F9E52137</gtr:id><gtr:title>A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>AhnByNnB1TQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B75B44A0-D33D-4EE2-AA7F-F5D4C3A1BCF8</gtr:id><gtr:title>The role of CHMP2B in frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab9e3dde384013eef79f476bf114e0e9"><gtr:id>ab9e3dde384013eef79f476bf114e0e9</gtr:id><gtr:otherNames>Urwin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>5DA2C12156C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E52DF3CB-A7C7-49C8-9323-6345845F9ECD</gtr:id><gtr:title>Reversal of pathology in CHMP2B-mediated frontotemporal dementia patient cells using RNA interference.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6817cf39c35b603be3577d48c7163b6b"><gtr:id>6817cf39c35b603be3577d48c7163b6b</gtr:id><gtr:otherNames>Nielsen TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn><gtr:outcomeId>pm_13002_22_22786763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>62DF6CE3-2344-4874-BFF9-E8F95EE5E2C6</gtr:id><gtr:title>Cortical volumes and atrophy rates in FTD-3 CHMP2B mutation carriers and related non-carriers.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d512c4f3d932c75c17a141788e59355b"><gtr:id>d512c4f3d932c75c17a141788e59355b</gtr:id><gtr:otherNames>Eskildsen SF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>39794172DF6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11B4EDDB-99AD-4A9A-BF8B-A1F221CC6BC3</gtr:id><gtr:title>A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3ab405150e2089e42f3d42e7d67f33a"><gtr:id>b3ab405150e2089e42f3d42e7d67f33a</gtr:id><gtr:otherNames>Lashley T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>FExChLyna3S</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49C4567A-0B13-478A-865D-1A557A6B1823</gtr:id><gtr:title>FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab9e3dde384013eef79f476bf114e0e9"><gtr:id>ab9e3dde384013eef79f476bf114e0e9</gtr:id><gtr:otherNames>Urwin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>PxSh8GRFvQG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D4F7F40-A276-42E0-89AE-815AAC5FA01F</gtr:id><gtr:title>Frontotemporal dementia linked to chromosome 3 (FTD-3)--current concepts and the detection of a previously unknown branch of the Danish FTD-3 family.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6466b708f9644403c318702ed53fc9ad"><gtr:id>6466b708f9644403c318702ed53fc9ad</gtr:id><gtr:otherNames>Lindquist SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>0099456FC6B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE510B0D-5D7E-4EB9-AFBC-1F197DB486B4</gtr:id><gtr:title>The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>XrZcbqFu9ma</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC1D6E6C-67C8-4135-AD9E-E2BCBBC220AD</gtr:id><gtr:title>Presymptomatic cerebral blood flow changes in CHMP2B mutation carriers of familial frontotemporal dementia (FTD-3), measured with MRI.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/905fddbf4e071e877959cc965ad7aa0b"><gtr:id>905fddbf4e071e877959cc965ad7aa0b</gtr:id><gtr:otherNames>Lunau L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_13002_22_22422914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>736EC1E2-9112-4D0C-AB4C-B1BF8C7C74A0</gtr:id><gtr:title>The role of ESCRT proteins in fusion events involving lysosomes, endosomes and autophagosomes.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa92e422db7ce647e1fd4d8f9f65c735"><gtr:id>aa92e422db7ce647e1fd4d8f9f65c735</gtr:id><gtr:otherNames>Metcalf D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>PcSMq7cxHEw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>229E06B0-EBFA-42A2-82B8-7F72CF8E063B</gtr:id><gtr:title>Frontotemporal dementia caused by CHMP2B mutations.</gtr:title><gtr:parentPublicationTitle>Current Alzheimer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8846d6564b676c6cf88dfef4d703f62b"><gtr:id>8846d6564b676c6cf88dfef4d703f62b</gtr:id><gtr:otherNames>Isaacs AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1567-2050</gtr:issn><gtr:outcomeId>Mkmsqp9suWC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A18379E1-D9D4-44C3-AD11-6ED9008DADAD</gtr:id><gtr:title>Novel types of frontotemporal lobar degeneration: beyond tau and TDP-43.</gtr:title><gtr:parentPublicationTitle>Journal of molecular neuroscience : MN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/515bfdcc03f3aef9a0610ccbd57d67f5"><gtr:id>515bfdcc03f3aef9a0610ccbd57d67f5</gtr:id><gtr:otherNames>Mackenzie IR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0895-8696</gtr:issn><gtr:outcomeId>RGEScEohjAJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A700356-91A5-40D8-9B6A-55340408CC91</gtr:id><gtr:title>Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e22465f44b042eeb56782567f6ced8dd"><gtr:id>e22465f44b042eeb56782567f6ced8dd</gtr:id><gtr:otherNames>Loy CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>S5cDmU3e7uU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7898EAF-CD30-490E-A020-614134E0D136</gtr:id><gtr:title>Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/738fdd28790b74d120b2b7e362223ce0"><gtr:id>738fdd28790b74d120b2b7e362223ce0</gtr:id><gtr:otherNames>Ghazi-Noori S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_13002_22_22366797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4C1FB41-7BAF-4BB8-9BF2-43EA3C81C65D</gtr:id><gtr:title>A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/267011d4d317d92cf9efc5eb7bbbc346"><gtr:id>267011d4d317d92cf9efc5eb7bbbc346</gtr:id><gtr:otherNames>Holm IE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>97C4C7786D2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CB10911-5102-40C0-84ED-AEDADA2E848B</gtr:id><gtr:title>TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander.</gtr:title><gtr:parentPublicationTitle>Mammalian genome : official journal of the International Mammalian Genome Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b340eec681d243ded9a96296147e0c6"><gtr:id>5b340eec681d243ded9a96296147e0c6</gtr:id><gtr:otherNames>Banks GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0938-8990</gtr:issn><gtr:outcomeId>11E96F13D8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E89AB445-C05D-4310-A4F4-40B4C68617B3</gtr:id><gtr:title>Presymptomatic generalized brain atrophy in frontotemporal dementia caused by CHMP2B mutation.</gtr:title><gtr:parentPublicationTitle>Dementia and geriatric cognitive disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1420-8008</gtr:issn><gtr:outcomeId>06AB25A6583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9904D14-0DCC-4779-ABB0-4E2B81982608</gtr:id><gtr:title>Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab9e3dde384013eef79f476bf114e0e9"><gtr:id>ab9e3dde384013eef79f476bf114e0e9</gtr:id><gtr:otherNames>Urwin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>LtotxeDranf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E457AC4F-D81B-4364-AB61-3220D45BC3B1</gtr:id><gtr:title>The heritability and genetics of frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>gXU8ZS13o5b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93FCE152-C23C-4021-99CA-4F82CEC17ED9</gtr:id><gtr:title>CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96a9bbe73354410988576c36694681de"><gtr:id>96a9bbe73354410988576c36694681de</gtr:id><gtr:otherNames>van der Zee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>7408DD21C41</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BC477F5-43A3-4BD7-8FE5-5163F9EC8CCC</gtr:id><gtr:title>Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/684ed4767cd99e6f1bb322f9aa19ee6a"><gtr:id>684ed4767cd99e6f1bb322f9aa19ee6a</gtr:id><gtr:otherNames>Filimonenko M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>E60B4C034A0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9BBB270-8BA7-41DB-A0B3-4F734BF66E70</gtr:id><gtr:title>Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/267011d4d317d92cf9efc5eb7bbbc346"><gtr:id>267011d4d317d92cf9efc5eb7bbbc346</gtr:id><gtr:otherNames>Holm IE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>KuLqHsyyHoQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F42697A8-96C6-47D3-AAD6-6F60AF1A73BC</gtr:id><gtr:title>A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f7fb44cb0e9d3dbae03fa9e859951a"><gtr:id>72f7fb44cb0e9d3dbae03fa9e859951a</gtr:id><gtr:otherNames>Beck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>DcKFSt3sECN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D58CD94-04B6-4762-BA70-80829F300730</gtr:id><gtr:title>Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>BzC8u8cGrmx</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123182015</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>